AbbVie's Cerevel buyout delivers as FDA gives go-ahead to 1st-in-class Juvmo in Parkinson's disease
The FDA has approved Juvmo, a first-in-class Parkinson's disease medication, validating AbbVie's $8.7 billion acquisition of Cerevel.
7 trends tracked about this subject — the full history, oldest to newest below.
The FDA has approved Juvmo, a first-in-class Parkinson's disease medication, validating AbbVie's $8.7 billion acquisition of Cerevel.
New reports warn that discontinuing GLP-1 weight-loss medications like Ozempic, Mounjaro, and Wegovy may increase the risk of heart attack and stroke.
Recent coverage highlights rising concerns over midlife dementia, stressing early evaluation and the risk of ignoring symptoms.
Nutrition experts and health outlets are highlighting plant-based protein sources that rival or exceed the protein content of traditional eggs.
7 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Major medical centers across the Midwest, including two Illinois hospitals, have secured top spots in the U.S. News and World Report's latest rankings.
Health experts are questioning if current protein intake levels are sufficient for healthy aging, sparking a trend toward increased dietary protein.